Search results for "Immune System Diseases"

showing 10 items of 442 documents

Sezernierter Interleukin-2-Rezeptor als Aktivitätsparameter der Sarkoidose*

2008

Serum sIL-2-R levels were measured in 28 sarcoidosis patients at multiple time points before, during, and after therapy, with a mean follow-up time of 10.2 +/- 5.2 months, and the results compared with the clinical activity of the disease. Before therapy, 20 out of 24 episodes with active disease exhibited elevated levels of sIL-2-R (918 +/- 362 U/ml). In inactive disease after tapering off corticoid therapy the sIL-2-R levels were 453 +/- 274 U/ml. Disease activity under therapy also correlated with sIL-2-R serum levels. 23 out of 29 episodes with signs of activity under therapy had elevated sIL-2-R levels (808 +/- 409 U/ml). Only three of 28 patients in whom disease activity ceased after …

medicine.medical_specialtybusiness.industryGeneral MedicineDiseasemedicine.diseaseGastroenterologyfemale genital diseases and pregnancy complicationsDisease activityPulmonary sarcoidosisimmune system diseaseshemic and lymphatic diseasesInternal medicineActive diseaseMultiple timeMedicineSarcoidosisbusinessInactive diseaseReceptorDMW - Deutsche Medizinische Wochenschrift
researchProduct

In Vitro Cytokine Production by HLA-B8, DR3 Positive Subjects

1994

It is well known that healthy subjects carrying the HLA-B8,DR3 haplotype may show an impairment of immune system, the T cells being the most affected. To gain insight into the mechanism(s) of the impairment displayed by these subjects, efforts have been centered on the study of in vitro cytokine production because of the pivotal role played by these mediators in the activation and control of several immune functions. The available results indicate that the ability to several immune functions. The available results indicate that the ability to produce interleukin-1 (IL-1), IL-2 and the soluble form of its receptor (sIL-2R) is impaired in HLA-B8,DR3 positive healthy subjects. To better charac…

AdultMalemusculoskeletal diseasesInterleukin 2Cellular immunitymedicine.medical_treatmentImmunologyAutoimmunityPeripheral blood mononuclear cellHLA-B8 AntigenInterferon-gammaHLA-DR3 AntigenImmune systemimmune system diseasesmedicineHumansImmunology and AllergyInterferon gammaPhytohemagglutininsInterleukin 6Cells CulturedInterleukin 4biologyInterleukin-6Receptors Interleukin-2Middle AgedRecombinant ProteinsCytokineAntibody FormationImmunologyLeukocytes Mononuclearbiology.proteinCytokinesInterleukin-2FemaleInterleukin-4medicine.drugAutoimmunity
researchProduct

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

2015

Abstract Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported. Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944,…

OncologyAdultMalemedicine.medical_specialtyEpidemiologyChronic lymphocytic leukemiamedicine.medical_treatmentFollicular lymphomaBiologyArticleBody Mass IndexYoung Adultimmune system diseasesRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseLymphangiogenesisAdiposityAgedRetrospective StudiesPolymorphism GeneticAbsolute risk reductionDNA NeoplasmMiddle Agedmedicine.diseaseObesityLymphomaCytokineOncologyIL1AImmunologyCytokinesFemaleLymphoma Large B-Cell DiffuseBody mass indexCancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
researchProduct

Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency.

2006

Recurrent abdominal attacks belong to the cardinal and most distressing symptoms of hereditary angioedema (HAE) due to C1 inhibitor deficiency. They are characterized by crampy pain, but may include vomiting, diarrhea, and other features. Detailed clinical data about the symptoms and course of abdominal attacks have not been reported.We retrospectively observed a total of 33,671 abdominal attacks in 153 patients with HAE including a prospectively examined subgroup of 23 patients. Symptoms, course, frequency of attacks, and complications were analyzed.The relation of mild, moderate, and severe attacks was 1:1.4:5.6 in the prospective part of the study. Extra-abdominal symptoms preceded the a…

AdultMalemedicine.medical_specialtyAllergyC1 inhibitor deficiencyComplement C1 Inactivator ProteinsDiagnosis DifferentialEcallantideimmune system diseasesImmunopathologymedicineHumanscardiovascular diseasesProspective StudiesAngioedemaskin and connective tissue diseasesSerpinsPain MeasurementRetrospective StudiesHepatologybusiness.industryGastroenterologyfood and beveragesRetrospective cohort studyMiddle Agedmedicine.diseaseDermatologySurgeryAbdominal Painmedicine.anatomical_structureEarly DiagnosisHereditary angioedemaAbdomenFemalebusinessComplicationComplement C1 Inhibitor Proteinmedicine.drugThe American journal of gastroenterology
researchProduct

Asthma and rhinoconjunctivitis comorbidity: United airway disease or inherited target organs?

2009

Garcia-Marcos L, Ruiz TR, Garcia-Hernandez G, Suarez-Varela MM, Valverde-Molina J, Sanchez-Solis M. Asthma and rhinoconjunctivitis comorbidity: United airway disease or inherited target organs? Pediatr Allergy Immunol 2010: 21: e142–e148. © 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard The idea of a united airway disease for asthma and rhinoconjunctivitis is supported by clinical and epidemiological data. However, many asthmatics do not have rhinoconjunctivitis and vice versa. The aim of this study was to investigate if the family history of a specific organ involvement is associated with the implication of the same organ in the allergic child. According to the organ invo…

MaleParentsmedicine.medical_specialtyAllergyDermatophagoides pteronyssinusPopulationImmunologyPopulationimmune system diseasesSurveys and QuestionnairesInternal medicineEpidemiologymedicineAnimalsHumansImmunology and AllergyFamily historyChildMedical History TakingeducationNoseRhinitisSkin TestsAsthmaeducation.field_of_studyDermatophagoides farinaebusiness.industryOdds ratioConjunctivitismedicine.diseaseComorbidityAsthmarespiratory tract diseasesmedicine.anatomical_structurePediatrics Perinatology and Child HealthImmunologyFemalebusinessPediatric Allergy and Immunology
researchProduct

313: A cDNA-based assay for donor-chimerism analysis of epidermal langerhans cells

2007

Transplantationsurgical procedures operativeimmune system diseasesbusiness.industryComplementary DNADonor chimerismMedicineHematologybusinessMolecular biologyBiology of Blood and Marrow Transplantation
researchProduct

Additional file 5: of Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

2019

Figure S4. A Western blot showing expression levels of anti-apoptotic proteins BCL-2 and MCL-1 in U266 and MM1S treated with different doses of trabectedin. B Representative dot plot of apoptosis induction and ROS production in U266 and MM1S cells after trabectedin-treatment respect to control, in presence or absence of ascorbic acid. C Western blot reporting protein expression of cell-cycle and DNA-damage regulators (p21, p-Chk2, RAD51 and gH2AX) in OPM2 cell line, after trabectedin treatment. D Representative immunohistochemistry showing gamma-h2ax foci (in brown) in the nuclei of U266 cells growth in matrigel-based spheroids, after 2.5 nM trabectedin treatment. E Surface expression of MI…

immune system diseaseshemic and lymphatic diseases
researchProduct

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.

2008

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long-acting beta2-agonist (LABA) combination with a short-acting beta2-agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline-defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is reco…

Budesonidemedicine.medical_specialtyExacerbationImmunologySeverity of Illness IndexPharmacotherapyimmune system diseasesFormoterol FumarateSeverity of illnessAdministration InhalationmedicineImmunology and AllergyAnimalsHumansAnti-Asthmatic AgentsIntensive care medicineBudesonideAsthmaInhalationbusiness.industrymedicine.diseaseAsthmarespiratory tract diseasesBudesonide/formoterolEthanolaminesPhysical therapyDrug Therapy CombinationFormoterolbusinessmedicine.drugAllergy
researchProduct

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis

2019

Antiphospholipid antibodies (aPLs) with complex lipid and/or protein reactivities cause complement-dependent thrombosis and pregnancy complications. Although cross-reactivities with coagulation regulatory proteins contribute to the risk for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aPLs retain reactivity with membrane lipid components and rapidly induce reactive oxygen species-dependent proinflammatory signaling and tissue factor (TF) procoagulant activation. Here, we show that lipid-reactive aPLs activate a common species-conserved TF signaling pathway. aPLs dissociate an inhibited TF coagulation initiation complex on the cell surface of m…

Male0301 basic medicineLipoproteinsImmunologyPlenary Paper030204 cardiovascular system & hematologyBiochemistryMonocytesThromboplastinProinflammatory cytokine03 medical and health sciencesTissue factor0302 clinical medicineTissue factor pathway inhibitorThrombinimmune system diseasesmedicineAnimalsHumansThromboplastinBlood CoagulationneoplasmsCells CulturedNADPH oxidasebiologyChemistryThrombosisCell BiologyHematologyComplement systemMice Inbred C57BL030104 developmental biologyAntibodies Antiphospholipidbiology.proteinCancer researchFemaleSignal transductionSignal Transductionmedicine.drugBlood
researchProduct